Key facts
- Marvix AI’s last known valuation is $17.0M (Feb 2026).
- It has raised $2.8M across 1 recorded rounds; the latest was Seed Round ($2.8M) in Sep 2025.
- Notable investors include Leo Capital, SeedToB Capital.
- Marvix AI has filed 1 Form D with the SEC, most recently Feb 2026 ($2.8M sold to 3 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Marvix AI
Funding rounds
1 roundsAbout Marvix AI
Developer of generative AI applications designed to automate administrative workflows in clinical environments. The company offers an AI-powered suite including ambient scribing for clinical notes, automated medical coding with ICD-10-CM and E/M modifiers, and additional productivity tools, enabling hospitals and healthcare practices to reduce clinician burnout, streamline documentation, and improve operational efficiency while allowing medical professionals to focus more on patient care.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Employees
- 21
- Website
- marvix.ai/
- Ownership
- Privately Held (backing)
Marvix AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Marvix AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Marvix AI in its N-PORT filings yet. We sweep new filings monthly.